每日低容量腹腔穿刺放液与难治性腹水患者临床并发症的关系
这项回顾性队列研究纳入2012至2020年住院的250例肝硬化难治性腹水且经颈静脉肝内门体分流术禁忌患者,比较植入装置(Alfapump或隧道式腹腔导管)每日低容量引流与标准治疗(反复大量腹腔穿刺放液并输注白蛋白)。装置组中确定1.5 L/d为估算低钠血症和急性肾损伤的界值;校正混杂因素后,引流≥1.5 L/d与低钠血症(HR 2.17,95%CI 1.24-3.78,P=0.006)和急性肾损伤(HR 1.43,95%CI 1.01-2.16,P=0.04)相关。倾向评分匹配后,引流≥1.5 L/d者较标准治疗组低钠血症(HR 1.67,95%CI 1.06-2.68,P=0.02)和急性肾损伤(HR 1.51,95%CI 1.04-2.18,P=0.03)风险更高;引流<1.5 L/d者并发症发生率未较标准治疗组升高。作者认为对每日引流≥1.5 L且不补充白蛋白的患者应谨慎。
要点
- 装置引流≥1.5 L/d且不补充白蛋白时,低钠血症风险升高(校正后HR 2.17,95%CI 1.24-3.78,P=0.006)。
- 装置引流≥1.5 L/d且不补充白蛋白时,急性肾损伤风险升高(校正后HR 1.43,95%CI 1.01-2.16,P=0.04)。
- 倾向评分匹配后,引流≥1.5 L/d者较标准治疗组低钠血症风险更高(HR 1.67,95%CI 1.06-2.68,P=0.02)。
- 倾向评分匹配后,引流≥1.5 L/d者较标准治疗组急性肾损伤风险更高(HR 1.51,95%CI 1.04-2.18,P=0.03)。
- 引流<1.5 L/d者并发症发生率未较标准治疗组升高,作者认为对引流≥1.5 L/d且不补充白蛋白者应谨慎。
适用人群与场景
- 肝硬化、难治性腹水且经颈静脉肝内门体分流术禁忌、2012至2020年住院的患者,接受装置植入(Alfapump或隧道式腹腔导管)或标准治疗(反复大量腹腔穿刺放液并输注白蛋白)。
诊断标准与关键阈值
- 装置引流患者中以1.5 L/d为界值估算低钠血症和急性肾损伤风险,引流≥1.5 L/d为高风险组,<1.5 L/d为低风险组。
研究设计与关键结果
- 回顾性队列研究纳入250例难治性腹水患者,装置植入组179例(72%;男125例[70%],女54例[30%],平均[SD]年龄59[11]岁),标准治疗组71例(28%;男41例[67%],女20例[33%],平均[SD]年龄54[8]岁)。
- 装置引流≥1.5 L/d与低钠血症相关(校正后HR 2.17,95%CI 1.24-3.78,P=0.006),与急性肾损伤相关(校正后HR 1.43,95%CI 1.01-2.16,P=0.04)。
- 倾向评分匹配后,引流≥1.5 L/d者较标准治疗组低钠血症风险更高(HR 1.67,95%CI 1.06-2.68,P=0.02),急性肾损伤风险更高(HR 1.51,95%CI 1.04-2.18,P=0.03)。
- 引流<1.5 L/d者并发症发生率未较标准治疗组升高。
证据类型、等级与局限
- 证据类型:回顾性队列研究;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对每日引流≥1.5 L且不补充白蛋白的难治性腹水患者,医生应谨慎。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The potential association of low-volume paracentesis of less than 5 L with complications in patients with ascites remains unclear, and individuals with cirrhosis and refractory ascites (RA) treated with devices like Alfapump or tunneled-intraperitoneal catheters perform daily low-volume drainage without albumin substitution. Studies indicate marked differences regarding the daily drainage volume between patients; however, it is currently unknown if this alters the clinical course.
OBJECTIVE: To determine whether the incidence of complications, such as hyponatremia or acute kidney injury (AKI), is associated with the daily drainage volume in patients with devices.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study of patients with liver cirrhosis, RA, and a contraindication for a transjugular intrahepatic portosystemic shunt who received either device implantation or standard of care (SOC; ie, repeated large-volume paracentesis with albumin infusion), and were hospitalized between 2012 and 2020 were included. Data were analyzed from April to October 2022.
INTERVENTIONS: Daily ascites volume removed.
MAIN OUTCOMES AND MEASURES: The primary end points were 90-day incidence of hyponatremia and AKI. Propensity score matching was performed to match and compare patients with devices and higher or lower drainage volumes to those who received SOC.
RESULTS: Overall, 250 patients with RA receiving either device implantation (179 [72%] patients; 125 [70%] male; 54 [30%] female; mean [SD] age, 59 [11] years) or SOC (71 [28%] patients; 41 [67%] male; 20 [33%] female; mean [SD] age, 54 [8]) were included in this study. A cutoff of 1.5 L/d or more was identified to estimate hyponatremia and AKI in the included patients with devices. Drainage of 1.5 L/d or more was associated with hyponatremia and AKI, even after adjusting for various confounders (hazard ratio [HR], 2.17 [95% CI, 1.24-3.78]; P = .006; HR, 1.43 [95% CI, 1.01-2.16]; P = .04, respectively). Moreover, patients with taps of 1.5 L/d or more and less than 1.5 L/d were matched with patients receiving SOC. Those with taps of 1.5 L/d or more had a higher risk of hyponatremia and AKI compared with those receiving SOC (HR, 1.67 [95% CI, 1.06-2.68]; P = .02 and HR, 1.51 [95% CI, 1.04-2.18]; P = .03), while patients with drainage of less than 1.5 L/d did not show an increased rate of complications compared with those receiving SOC.
CONCLUSIONS AND RELEVANCE: In this cohort study, clinical complications in patients with RA performing low-volume drainage without albumin infusion were associated with the daily volume drained. Based on this analysis, physicians should be cautious in patients performing drainage of 1.5 L/d or more without albumin infusion.
参考来源
- Tergast TL, Griemsmann M, Stockhoff L, et al. Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites. JAMA Netw Open. 2023. PMID: 37410459. doi:10.1001/jamanetworkopen.2023.22048
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。